Sirtex Medical
Sirtex Medical Limited is a life-sciences company based in North Sydney, Australia, specializing in the development and delivery of innovative oncology treatments. The company focuses on using novel small particle technology, specifically through its principal product, SIR-Spheres Y-90 resin microspheres. This targeted radioactive treatment is designed for patients suffering from primary and secondary metastatic liver cancer, utilizing selective internal radiation therapy (SIRT) to deliver treatment directly to the liver. With operations extending across the Asia-Pacific, Europe, the Middle East, Africa, and both North and South America, Sirtex Medical aims to enhance treatment options and outcomes for liver cancer patients globally. Since September 2018, Sirtex has operated as a subsidiary of CDH Genetech Limited.
Nanospectra Biosciences
Series B in 2020
Nanospectra Biosciences, Inc. is a medical device company based in Houston, Texas, specializing in the development and commercialization of particle-based therapies aimed at the selective and precise thermal destruction of solid tumors. The company's primary offering is AuroLase therapy, which employs AuroShell particles and other nanomaterials to achieve thermal ablation of tumors while minimizing damage to surrounding healthy tissue. In addition to its therapeutic products, Nanospectra also provides research-use-only nanoparticles with specific optical characteristics, such as gold nanoshells, and offers custom production services for various medical and commercial applications. Founded in 2001, Nanospectra Biosciences is focused on advancing innovative solutions in cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.